Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 11/20 | 1.00 |
| ▸ | TMPRSS4 | Q9NRS4 | 11/20 | 1.00 |
| ▸ | P2RX4 | Q99571 | 6/20 | 1.00 |
| ▸ | P2RX7 | Q99572 | 6/20 | 1.00 |
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | IKBKB | O14920 | 1/20 | 0.68 |
| ▸ | CHUK | O15111 | 1/20 | 0.68 |
| ▸ | KDR | P35968 | 1/20 | 0.68 |
| ▸ | FLT3 | P36888 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | MYLK | Q15746 | 1/20 | 0.68 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.68 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29454776 | 0.88 | P2RX1 (1.00) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL2169619 | 0.88 | P2RX1 (1.00) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL11932152 | 0.87 | P2RX1 (1.00) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL14886091 | 0.87 | P2RX1 (0.77) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL330564 | 0.86 | P2RX1 (0.76) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL330059 | 0.85 | TMPRSS4 (0.90) | P2RX1TMPRSS4P2RX4P2RX7MEN1 | |
| SCHEMBL330901 | 0.85 | P2RX1 (0.74) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL331484 | 0.85 | P2RX1 (0.74) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL330475 | 0.85 | P2RX1 (0.74) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 | |
| SCHEMBL330690 | 0.85 | P2RX1 (0.74) | P2RX1TMPRSS4P2RX4P2RX7KCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2020-02-06 | — | — | US | claimed |
| US-20190077772-A1 | CHEMICAL MODULATORS OF IMMUNE CHECKPOINTS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2019-03-14 | — | — | US | claimed |
| EP-3313388-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | Duke University (US) | 2018-05-02 | — | — | EP | claimed |
| WO-2016210289-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY (US) | 2016-12-29 | — | — | WO | claimed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | claimed |
| US-12496308-B2 | Methods of administering a pharmaceutically acceptable salt of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate | AEROMICS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-12213987-B2 | Prodrug salts | AEROMICS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240299425-A1 | FORMULATIONS | AEROMICS, INC. | 2024-09-12 | — | — | US | disclosed |
| US-11801254-B2 | Pharmaceutical compositions and methods of making pharmaceutical compositions comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate | AEROMICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20220143048-A1 | NOVEL PRODRUG SALTS | AEROMICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7626042-B2 | O-substituted hydroxyaryl derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11801254-B2 | Pharmaceutical compositions and methods of making pharmaceutical compositions comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate | PLCG2, DCTPP1, PLCG1 | P2RX1 790/4885TMPRSS4 1479/4885P2RX4 274/4885 |
| US-12496308-B2 | Methods of administering a pharmaceutically acceptable salt of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate | SLC34A2, SLC20A2, SLC34A3 | P2RX1 1611/4885TMPRSS4 1440/4885P2RX4 674/4885 |
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | IL1A, TNF, NFKBIA | P2RX1 2507/4885TMPRSS4 4278/4885P2RX4 3900/4885 |
| US-20240299425-A1 | FORMULATIONS | DCPS, PPIP5K2, PRCP | P2RX1 883/4885TMPRSS4 871/4885P2RX4 346/4885 |
| US-12213987-B2 | Prodrug salts | AQP4, AQP1, AQP3 | P2RX1 556/4885TMPRSS4 1144/4885P2RX4 649/4885 |
| US-20190077772-A1 | CHEMICAL MODULATORS OF IMMUNE CHECKPOINTS AND THERAPEUTIC USE | CD274, PDCD1, PDCD1LG2 | P2RX1 1425/4885TMPRSS4 1233/4885P2RX4 1249/4885 |
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | SFRP1, FZD7, WNT1 | P2RX1 3423/4885TMPRSS4 2074/4885P2RX4 3784/4885 |
| US-20220143048-A1 | NOVEL PRODRUG SALTS | AQP4, AQP1, AQP3 | P2RX1 543/4885TMPRSS4 1033/4885P2RX4 640/4885 |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | RELA, NFKBIA, NFE2 | P2RX1 3644/4885TMPRSS4 3984/4885P2RX4 4206/4885 |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | TMPRSS2, TMPRSS4, PRSS2 | P2RX1 4273/4885TMPRSS4 2/4885P2RX4 3330/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | P2RX1 2316/4885TMPRSS4 3292/4885P2RX4 3466/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | P2RX1 910/4885TMPRSS4 2067/4885P2RX4 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.